The Hollowing Out of America’s Medicine Cabinet
For the first time on record, the United States makes barely a quarter of the medicine it needs.
For the first time on record, the United States makes barely a quarter of the medicine it needs.
President Trump’s revision to the steel tariff in 2025 was meant to fix the tariff inversion problem – situations where we tariff steel imports, but not things made of steel. Putting a tariff on metal can imports, but not metal cans filled with food, is a perfect example of mindless tariff inversion driving offshoring. This precise problem was solved and settled in 1930, and Commerce and USTR can fix it at any time with existing authority.
For years, the most critical link in our drug supply chain — the upstream chemistry — has been invisible to our own regulators. A medicine finished in Europe is not necessarily a European medicine, and this rule finally begins to expose that fiction.
Last week, the White House declared an emergency under Section 318 of the Tariff Act of 1930 and suspended, for eight months, the collection of anti-dumping and countervailing duties on phosphate fertilizer from the Kingdom of Morocco.
Years ago, CPA warned that China was using American clean-energy tax credits to capture our solar industry — and we led the fight to slam that door shut.
President Trump might be fine with upending the United States-Mexico-Canada Agreement (USMCA) ahead of the July 1 review deadline, but the House Agriculture Committee is not.
China is quietly making a move on one of America’s most critical industrial materials — copper. Texas is helping them do it.
The government increasingly sees critical minerals, battery materials and components, and refining as strategic industrial assets rather than low value goods often burdened by environmental regulations.
For too long, foreign actors with no real U.S. presence have been able to import into the American market while shielding themselves from the duties, penalties, and laws that domestic producers and legitimate U.S. importers must obey. The order takes aim squarely at that imbalance.
Lawmakers from member states of the European Union agreed to measures last week to stop drug shortages and fix chronic Asian dependencies for critical medicines, this time spurred by worries over the antibiotics supply chain.